Leveraging Psychological Autopsies to Accelerate Research Into Stimulant Overdose Mortality (NCT06076564) | Clinical Trial Compass
CompletedNot Applicable
Leveraging Psychological Autopsies to Accelerate Research Into Stimulant Overdose Mortality
United States176 participantsStarted 2022-06-06
Plain-language summary
In the LASSO study, the investigators will identify 100 stimulant overdose decedents (divided among stimulant-only, and stimulant with fentanyl), conduct informant interviews (including scales and qualitative data), and gather data from the postmortem investigation (e.g., vital records, toxicology, autopsy, case narrative, death scene photographs) and medical record abstraction. Subsequently, study staff will conduct qualitative interviews with 40-60 living people who use stimulants (aiming for half methamphetamine, half cocaine) to explore elements of resilience and risk reduction strategies. This study aims to contribute to the eventual design of interventions to reduce stimulant overdose mortality.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. are aware the decedent used substances in the past year prior the to date of death AND
. have been in contact with the decedent in the past year prior to the date of death by phone, email, or in person
. are aware the decedent used substances in the past 30 days prior to the date of death and
. have been in contact with the decedent in person in the past year prior to the date of death.
. ≥18 years of age,
. Used cocaine or methamphetamine for ≥5 years,
. Used cocaine or methamphetamine for ≥10 out of the past 30 days, AND
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Clinical antecedents to stimulant overdose.
Timeframe: One year prior to the date of death.
2
Antecedent patterns between stimulant overdose deaths with and without fentanyl.
Timeframe: One year prior to the date of death.
3
Resilience factors and risk reduction strategies among living persons who use stimulants.
. Matched to a decedent on age, race/ethnicity, gender, and neighborhood distribution of decedents of the methamphetamine/no opioid and cocaine/no opioid decedents.
Exclusion criteria
. Used both cocaine and methamphetamine ≥5 of past 30 days,